More evidence is needed to understand the impact of resistance mechanisms on clinical outcomes for patients with EGFR-mutated NSCLC, as well as patient, social, and behavioral factors that may be associated with particular resistance mechanisms. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.